✨ Your Portfolio is fetched and updated from zerodha.

Eris Lifesciences Ltd.

ERIS

Market Cap
₹17,580 Cr.
P/E
50.45

Eris Lifesciences Ltd.

  • Eris Lifesciences
  • Caplin Point Lab
  • Astrazeneca Pharma I
  • TJI Pharma - Small Cap
FAQs on Eris Lifesciences Ltd. Shareprice

Eris Lifesciences has given lower returns compared to its competitors.
Eris Lifesciences has grown at ~7.45% over the last 7yrs while peers have grown at a median rate of 9.8%

Yes, Eris Lifesciences is expensive.
Latest PE of Eris Lifesciences is 50.45, while 3 year average PE is 28.47.
Also latest EV/EBITDA of Eris Lifesciences is 23.94 while 3yr average is 20.29.

View FAQ's On Business
Growth Table
  • Eris Lifesciences Ltd.
  • Caplin Point Lab
  • Astrazeneca Pharma I
Balance Sheet
  • Eris Lifesciences Ltd.
  • Caplin Point Lab
  • Astrazeneca Pharma I
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Eris Lifesciences Ltd.
  • Caplin Point Lab
  • Astrazeneca Pharma I
Cash Flow
  • Eris Lifesciences Ltd.
  • Caplin Point Lab
  • Astrazeneca Pharma I
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Eris Lifesciences Ltd.
  • Caplin Point Lab
  • Astrazeneca Pharma I
Quarterly Results
  • Eris Lifesciences Ltd.
  • Caplin Point Lab
  • Astrazeneca Pharma I
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Eris Lifesciences Ltd. Financials

Balance sheet of Eris Lifesciences is strong.
But short term working capital might become an issue for this company.

Yes, The debt of Eris Lifesciences is increasing.
Latest debt of Eris Lifesciences is ₹2,489 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹58.78 Crs.

The profit is oscillating.
The profit of Eris Lifesciences is ₹367 Crs for TTM, ₹392 Crs for Mar 2024 and ₹382 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Eris Lifesciences latest dividend payout ratio is 26.15% and 3yr average dividend payout ratio is 23.14%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech